Urinary Prostaglandin E2 Metabolite and Pancreatic Cancer Risk: Case-Control Study in Urban Shanghai
Open Access
- 13 February 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (2) , e0118004
Abstract
Pancreatic cancer has been increasing in importance in Shanghai over the last four decades. The etiology of the disease is still unclear. Evidence suggests that the COX-2 pathway, an important component of inflammation, may be involved in the disease. We aimed to evaluate the association between urinary prostaglandin E2 metabolite (PGE-M) level and risk of pancreatic cancer. From a recent population-based case-control study in Shanghai, 200 pancreatic ductal adenocarcinoma cases and 200 gender- and age- frequency matched controls were selected for the present analysis. Urinary PGE-M was measured with a liquid chromatography/mass spectrometric assay. Adjusted unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). A positive association was observed between PGE-M leve and pancreatic cancer risk: OR = 1.63 (95% CI 1.01–2.63) for the third tertile compared to the first. Though the interactions were not statistically significant, the associations tended to be stronger among subjects with diabetes history (OR = 3.32; 95% CI 1.20–9.19) and higher meat intake (OR = 2.12; 95% CI 1.10–4.06). The result suggests that higher urinary PGE-M level may be associated with increased risk of pancreatic ductal adenocarcinoma.Keywords
This publication has 36 references indexed in Scilit:
- Association between Urinary Prostaglandin E2 Metabolite and Breast Cancer Risk: A Prospective, Case–Cohort Study of Postmenopausal WomenCancer Prevention Research, 2013
- ABO Blood Group and Risk of Pancreatic Cancer: A Study in Shanghai and Meta-AnalysisAmerican Journal of Epidemiology, 2013
- Urinary Prostaglandin E2 Metabolite and Risk for Colorectal AdenomaCancer Prevention Research, 2012
- Survival in Population-based Pancreatic Cancer Patients: San Francisco Bay Area, 1995-1999American Journal of Epidemiology, 2011
- Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control studyBritish Journal of Cancer, 2010
- Intra-Person Variation of Urinary Biomarkers of Oxidative Stress and InflammationCancer Epidemiology, Biomarkers & Prevention, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- Urinary Prostaglandin E2 Metabolite and Gastric Cancer Risk in the Shanghai Women's Health StudyCancer Epidemiology, Biomarkers & Prevention, 2009
- Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signalingCancer Letters, 2009
- Delayed Progression of Pancreatic Intraepithelial Neoplasia in a Conditional KrasG12D Mouse Model by a Selective Cyclooxygenase-2 InhibitorCancer Research, 2007